DOES DOXORUBICIN CONTAINING CHEMOTHERAPY CHANGE METABOLIC LIVER FUNCTION DURING TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA?

J. Kolarović ,
J. Kolarović

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

N. Konstantinidis ,
N. Konstantinidis

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

N. Kaćanski ,
N. Kaćanski

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

J. Katanić
J. Katanić

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

Published: 01.01.2011.

Volume 39, Issue 1 (2011)

pp. 33-37;

https://doi.org/10.70949/pramed201101393K

Abstract

Doxorubicin is antitumor antibiotic extensively metabolized in the liver, and liver antioxidant capacity, including that provided by glutathione production. The aim of this study was to investigate whether doxorubicin containing chemotherapy changes metabolic liver function during treatment of childhood acute lymphoblastic leukaemia. Total protein concentration in serum, concentration of total, conjugated and non conjugated bilirubin, activity of aspartat aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (ãGT), lactate dehydrogenase and creatin kinase activity were measured before and after treatment with doxorubicin containing chemotherapy and in the control group. Caffeine was applied as metabolic marker via controlled consummation of Coca-Cola and 8-hour urine was collected immediately afterwards. In the collected samples, urinary thioethers and caffeine metabolites concentrations were measured. Chemotherapeutic regiment established for initial treatment of childhood ALL containing prednisone, vincristine, doxorubicin and L-asparaginase did not alter metabolic liver function. This regiment did not change liver enzyme activity. Applied chemotherapy also did not alter caffeine biotransformation, but it did increase urinary thioethers excretion. 

Keywords

References

1.
Cvetković P, Stojimirović E, Janić D. Treatment of acute lymphoblastic leukemia: The results of YU 0184 and 0187 protocols. Bilt Hematol. 23(1–2):43–6.
2.
M MK, JC S, JK M. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity. Phytother Res. 19:1030–7.
3.
Al-Tonbary Y, Al-Haggar M, El-Ashry R. Vitamin E and N-acetylcysteine as antioxidant adjuvant therapy in children with acute lymphoblastic leukemia. Adv Hematol. 2009.
4.
Cvetković P. Akutne limfoblastne leukemije non-B.
5.
Aviles A, Herrera J, Ramos E. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med. 108:912–3.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by